Microscopic image of neurons

Policies

Sponsoring Institution Requirements

Investigators may apply from accredited academic medical centers, research institutions or universities in the U.S., U.S. territories and Canada. Applications must be written in English. The sponsoring institution must ensure the necessary facilities and infrastructure are in place to execute the planned research project. The institution must also accept the award conditions, including the Budget Use of Funds and provide governance over fund expenditures.

Sponsoring institutions must safeguard the rights and welfare of individuals who participate as subjects in research activities. In the U.S., the proposed activities must be reviewed through an Institutional Review Board as specified by the U.S. Department of Health and Human Services Office for Human Research Protections, HHS OHRP. In Canada, the rights and welfare of participants are to be safeguarded through adherence to the policies and regulations of the Interagency Advisory Panel on Research Ethics / Le Groupe en Ethique de la Recherche, as well as any additional provincial regulations as applicable. Clinical protocols must be approved by an appropriately convened Research Ethics Board (REB). Proof of ACC and/or REB approvals are not required at the time of submission, but must be provided as part of the formal Grant Agreement by selected grantees.

Additionally, the grantee’s institution must assure appropriate compliance of animal studies. In the U.S., IRB approval and IACUC numbers are not required at the time of application, but must be provided for final signature of the Grant Agreement, which will be sent to the grantees shortly after they have been selected. In Canada, for animal studies, all work must adhere to the standards of the Canadian Council on Animal Care / Conseil Canadien De Protection Des Animaux with protocols approved by an appropriately convened Animal Care Committee (ACC).

Additionally, sponsoring institutions must adhere to current guidelines regarding financial conflict of interest, recombinant DNA and research misconduct.

Confidentiality

Members of Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute involved in reviewing applications are required to complete mutual Confidentiality & Disclosure Agreements to protect confidential applicant submissions.

Non-public applicant information is always kept confidential (and limited in distribution to the reviewers, Harrington Discovery Institute and Alzheimer’s Drug Discovery Foundation administrative teams). The abstract summary, including the applicant’s name and institutional affiliation, for those selected as Harrington Scholars may be used by Harrington Discovery Institute for publicity and marketing purposes (on the Harrington Discovery Institute website, new releases, etc.) at Harrington Discovery Institute’s sole discretion.

Applicants acknowledge that University Hospitals Health System may conduct research that is related to, or competitive with, proposals submitted by applicants, but University Hospitals Health System commits not to use information submitted by applications in connection with research.

Harrington Scholar Review Panel

The review panel will consist of subject matter experts with specialized scientific expertise in the area(s) designated in the application, as well as seasoned professionals with expertise in drug development and commercialization.

Projects will be assessed based on:

  • Quality of the science and the scientist
  • Novelty and innovative quality of the work
  • Potential for impact on human health

Applicants who fail to fill out their applications by the deadline and/or in accordance with the detailed instructions are subject to disqualification at the outset of the review period or any time during the review period.

Comments from Review Committee

Harrington Discovery Institute is unable to provide reviewers’ comments or feedback.

Annual Scientific Symposium

Part of Harrington Discovery Institute’s mission is to build a broad connected community of physician-scientist-innovators. Harrington Discovery Institute will hold an annual symposium that awardees are required to attend.

The Harrington Scientific Symposium, held in late spring in Cleveland, Ohio, will bring together drug development experts, national disease foundation leadership, and international leaders in medicine and Harrington Scholars. Awardees are expected to present their project and findings-to-date. A stipend for travel and lodging will be provided by Harrington Discovery Institute, subject to the terms of the Award Agreement.

Use of Funds

  • General: No more than $10,000 of the total grant can be used for capital expenditures or equipment. The award may only be used for direct project expenses, not for institutional overhead.
  • Salary: The award may be used to cover salaries for post-docs equivalent to the percentage of effort devoted to the project. Please note that PI’s salary is limited to 10% of the total award amount.
  • Travel: The award may not be used for travel, meetings, professional fees, publication fees, etc.

Intellectual Property Guidelines

Harrington Discovery Institute does not claim any rights whatsoever to patents, copyrights or trademarks to intellectual property (IP) created as a result of work sponsored by a Harrington grant.

  • On all aspects of Intellectual Property, Principal Investigators are encouraged to confer with their technology transfer office and/or office of sponsored programs for guidance. ADDF-Harrington Scholars may seek input and advice on patent protection from Harrington Discovery Institute’s Innovation Support Center, which also claims no rights whatsoever to IP.
  • Awardees should take measures to ensure protection of any Intellectual Property in accord with Federal and institutional requirements.

Scientific Reporting & Review of Progress

Yearly renewal of the award is dependent on timely submission of a written progress report, as well as attendance at Harrington Discovery Institute’s Scientific Symposium.

Changes to Project

A significant change in the project scope or work should be discussed with Harrington Discovery Institute’s Program Director and Chief Scientific Officer.

Awards may be transferred to another institution that agrees to assume the Policies, Terms & Conditions of the agreement. Permission to transfer the award to another institution must be obtained from Harrington Discovery Institute’s Chief Scientific Officer.

Compliance & Administrative Matters

Awards are managed by Harrington Discovery Institute. Harrington Discovery Institute staff will assure compliance with program policies and will be responsible for all administrative matters.

The Principal Investigator and his/her institution are solely responsible for execution of the project, including compliance with all relevant Federal and State laws and guidelines.

Harrington Discovery Institute reserves the right to refine and amend policies as required.

Questions

Any questions should be directed to HDIQuestions@HarringtonDiscovery.org.

The Harrington Project for Discovery & Development

Discover
Advance
Commercialize
Breakthrough Medicine